Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Keren Rouvinov; Karen Nalbandyan; Victor Kozlov; Nir Peled; Alexander Yakobson

doi:10.1159/000495980

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Keren Rouvinov, Karen Nalbandyan, Victor Kozlov, Nir Peled, Alexander Yakobson

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

Original language	English
Pages (from-to)	29-32
Number of pages	4
Journal	Case Reports in Oncology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1159/000495980
State	Published - 1 Jan 2019
Externally published	Yes

Keywords

Aplastic anemia
Immunotherapy
Melanoma
Nivolumab
Programmed death 1 inhibitor

ASJC Scopus subject areas

Oncology

Access to Document

10.1159/000495980

Cite this

@article{4e0c334bfc194aaf8ae4412440975e51,

title = "Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma",

abstract = "Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.",

keywords = "Aplastic anemia, Immunotherapy, Melanoma, Nivolumab, Programmed death 1 inhibitor",

author = "Keren Rouvinov and Karen Nalbandyan and Victor Kozlov and Nir Peled and Alexander Yakobson",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s). Published by S. Karger AG, Basel.",

year = "2019",

month = jan,

day = "1",

doi = "10.1159/000495980",

language = "English",

volume = "12",

pages = "29--32",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

AU - Rouvinov, Keren

AU - Nalbandyan, Karen

AU - Kozlov, Victor

AU - Peled, Nir

AU - Yakobson, Alexander

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

AB - Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

KW - Aplastic anemia

KW - Immunotherapy

KW - Melanoma

KW - Nivolumab

KW - Programmed death 1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85059878575&partnerID=8YFLogxK

U2 - 10.1159/000495980

DO - 10.1159/000495980

M3 - Article

C2 - 30792642

AN - SCOPUS:85059878575

SN - 1662-6575

VL - 12

SP - 29

EP - 32

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this